Paediatrics

Top Medical News
Ceftolozane/tazobactam safe, effective in complicated UTI
Stephen Padilla, 2 days ago
Combination therapy with ceftolozane and tazobactam demonstrates a favourable safety profile in children with complicated urinary tract infection (cUTI) similar to that of meropenem and to the previously reported safety profile in adults with cUTI, a study has shown.
Low-concentration atropine eye drops may reduce myopia incidence in high-risk children
Sarah Cheung, 2 days ago

Researchers from the Chinese University of Hong Kong (CUHK) have conducted the world’s first study to show that nightly use of low-concentration (0.05 percent) atropine eye drops may reduce the incidence of myopia in high-risk children.

Acetaminophen use during pregnancy poses no risk of adverse cognitive effects in babies
4 days ago
Children born to mothers who used acetaminophen during pregnancy do not appear to have poor cognitive development at 4 years of age, as shown in a study.
Women, minorities remain underrepresented in paediatric cardiology
4 days ago
The presence of women in paediatric cardiology remains inadequate, while that of underrepresented minorities in medicine (URMM) is very limited, reveals a recent study.
Peanut allergy guideline adherence remains low in US
Stephen Padilla, 5 days ago
Children who are allergic to peanuts may benefit from two immunotherapies, one oral and another epicutaneous or on-the-skin, which have demonstrated safety and efficacy in separate studies presented at the recent AAAAI 2023.
G-POEM safe, effective for infants with CHPS
5 days ago
Treatment with the minimally invasive gastric peroral endoscopic pyloromyotomy (G-POEM) is not only safe and feasible but also effective for infants with congenital hypertrophic pyloric stenosis (CHPS), according to a recent study, noting acceptable clinical response in the short term.
VANGUARD sets the stage for a novel biologic in HAE
Elvira Manzano, 6 days ago
Monthly injections of the investigational biologic garadacimab substantially reduced the mean attack rate in patients with hereditary angioedema (HAE) in the phase III VANGUARD trial.
Special Reports
Kids hard-hit by Delta; which ART performs best?
Elvira Manzano, 24 Oct 2021
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
ID NOW rapid molecular assay an effective COVID-19 test for kids
Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Combined Ag/Ab rapid testing boosts case-finding in COVID-19
Elvira Manzano, 29 Jul 2021
A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.
Navigating the CPP patient journey – case-based discussion for nurses
06 May 2021
In a webinar held on 27 March 2021, paediatric endocrinology nurses Karen Blair, Kate Davies, and Siti Zarina Yaakop shared insights and clinical experience based on their frontline roles in caring for patients with central precocious puberty (CPP) and supporting their family members.
A Guide on Primary Immunodeficiency Disease and Allergies
05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

Immunotherapy sparks hope for paediatric ALL
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.
Expert consensus: Patient profile should guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Conference Reports
Labetalol, nifedipine equally effective for chronic hypertension in pregnancy
Elaine Soliven, 23 Feb 2023
Treatment with either labetalol or nifedipine is similarly effective in reducing adverse maternal outcomes among women with mild chronic hypertension (CHTN) in pregnancy, according to a study presented at SMFM 2023.
Vacuum-induced device controls postpartum haemorrhage in just 5 mins
Elvira Manzano, 17 Feb 2023
Uncontrolled postpartum haemorrhage (PPH) is a life-threatening complication of childbirth that is temporarily managed with uterine balloon tamponade. At SMFM 2023, researchers from the US presented findings for a new device that could control PPH safely and effectively in just 5 minutes.
Single-dose azithromycin during labour prevents maternal death, sepsis
Elaine Soliven, 15 Feb 2023
Treatment with a single oral dose of azithromycin, given to women in labour who were planning a vaginal birth, significantly reduced the risk of maternal death or sepsis, according to the A-PLUS* trial presented at SMFM 2023.
Skin biomarkers predict AD risk, severity in newborns
Elvira Manzano, 27 Oct 2022
Predicting which newborn will go on to develop atopic dermatitis (AD) and how severe it will be is now feasible, according to the BABY* study.
Ruxolitinib improves repigmentation in vitiligo through 52 weeks
Elaine Soliven, 21 Oct 2022
Long-term use of ruxolitinib cream continued to improve facial and total body repigmentation in patients with nonsegmental vitiligo from 24 to 52 weeks, according to an updated pooled analysis of the phase III TRuE-V1* and TRuE-V2** studies presented at EADV 2022.
Lebrikizumab efficacy in atopic dermatitis maintained at 1 year
Roshini Claire Anthony, 12 Oct 2022

Maintenance lebrikizumab monotherapy appears to improve outcomes in patients with moderate-to-severe atopic dermatitis (AD), according to results of the phase III ADvocate1 and ADvocate2 trials.

ALLEGRO-LT shows long-term benefit of ritlecitinib for alopecia areata
Audrey Abella, 21 Sep 2022
In the interim analysis of the ongoing phase III ALLEGRO-LT trial, the investigational oral JAK3*/TEC inhibitor ritlecitinib demonstrated long-term safety and remarkable scalp hair regrowth in adults and adolescents with alopecia areata (AA).